Diagnostic technologies for neuroblastoma
Leena KhelifaDepartment of Chemical Engineering, Imperial College London, South Kensington, London, SW7 2BU, UKYubing HuDepartment of Chemical Engineering, Imperial College London, South Kensington, London, SW7 2BU, UKJennifer TallDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UKRasha KhelifaFaculty of Medicine, Imperial College London, South Kensington, SW7 5NH, UKAmina AliFaculty of Medicine, Imperial College London, South Kensington, SW7 5NH, UKEvon PoonDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UKMohamed Zaki KhelifaFaculty of Medicine, Imperial College London, South Kensington, SW7 5NH, UKGuowei YangFaculty of Medicine, Imperial College London, South Kensington, SW7 5NH, UKCatarina JonesSchool of Electronics and Computer Science, University of Southampton, Southampton, SO17 1BJ, UKRosalia MoredduInstitute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UKNan JiangWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, ChinaSavaş TaşoğluResearch Center for Translational Medicine, Koc University, Istanbul 34450, TurkeyLouis CheslerChildren's and Young People's Unit, Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, UKAli K. YetisenDepartment of Chemical Engineering, Imperial College London, South Kensington, London, SW7 2BU, UK
2025en
ABI
Annotatsiya
amplification and microRNAs (miRNAs). Using POC devices to detect high-risk biomarkers in biofluids such as blood and urine, offers a non-invasive approach to diagnosis of neuroblastoma, enabling early screening at a population level as well as real-time health monitoring at home. This is critical to mitigating long-term morbidity associated with late diagnosis and unnecessary treatment, in turn improving outcomes for neuroblastoma patients.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
4 ta iqtibos0 ta foydalanilgan manba